FI4199922T3 - (1r,3s)-3-((5-syano-4-fenyylitiatsol-2-yyli)karbamoyyli)syklopentaani-1-karboksyylihappo käytettäväksi hengitystietautien hoidossa - Google Patents
(1r,3s)-3-((5-syano-4-fenyylitiatsol-2-yyli)karbamoyyli)syklopentaani-1-karboksyylihappo käytettäväksi hengitystietautien hoidossa Download PDFInfo
- Publication number
- FI4199922T3 FI4199922T3 FIEP21765908.5T FI21765908T FI4199922T3 FI 4199922 T3 FI4199922 T3 FI 4199922T3 FI 21765908 T FI21765908 T FI 21765908T FI 4199922 T3 FI4199922 T3 FI 4199922T3
- Authority
- FI
- Finland
- Prior art keywords
- compound
- use according
- administered
- treatment
- dose
- Prior art date
Links
- 208000023504 respiratory system disease Diseases 0.000 title claims 3
- MSZKZEFOAPULKG-NWDGAFQWSA-N (1r,3s)-3-[(5-cyano-4-phenyl-1,3-thiazol-2-yl)carbamoyl]cyclopentane-1-carboxylic acid Chemical compound C1[C@H](C(=O)O)CC[C@@H]1C(=O)NC1=NC(C=2C=CC=CC=2)=C(C#N)S1 MSZKZEFOAPULKG-NWDGAFQWSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 21
- 208000006673 asthma Diseases 0.000 claims 3
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 2
- 201000009961 allergic asthma Diseases 0.000 claims 2
- 210000003979 eosinophil Anatomy 0.000 claims 2
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 2
- 210000005259 peripheral blood Anatomy 0.000 claims 2
- 239000011886 peripheral blood Substances 0.000 claims 2
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 230000003510 anti-fibrotic effect Effects 0.000 claims 1
- 229940092705 beclomethasone Drugs 0.000 claims 1
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 claims 1
- 229950000321 benralizumab Drugs 0.000 claims 1
- 229940124630 bronchodilator Drugs 0.000 claims 1
- 239000000168 bronchodilator agent Substances 0.000 claims 1
- 229960004436 budesonide Drugs 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000013066 combination product Substances 0.000 claims 1
- 229940127555 combination product Drugs 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 229960001334 corticosteroids Drugs 0.000 claims 1
- 239000013078 crystal Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229950003468 dupilumab Drugs 0.000 claims 1
- 230000002327 eosinophilic effect Effects 0.000 claims 1
- 229960002714 fluticasone Drugs 0.000 claims 1
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 claims 1
- 229960002848 formoterol Drugs 0.000 claims 1
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 claims 1
- 229960002411 imatinib Drugs 0.000 claims 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 claims 1
- 229950002183 lebrikizumab Drugs 0.000 claims 1
- 229960005108 mepolizumab Drugs 0.000 claims 1
- 229960001664 mometasone Drugs 0.000 claims 1
- QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 claims 1
- XZXHXSATPCNXJR-ZIADKAODSA-N nintedanib Chemical compound O=C1NC2=CC(C(=O)OC)=CC=C2\C1=C(C=1C=CC=CC=1)\NC(C=C1)=CC=C1N(C)C(=O)CN1CCN(C)CC1 XZXHXSATPCNXJR-ZIADKAODSA-N 0.000 claims 1
- 229960004378 nintedanib Drugs 0.000 claims 1
- 208000001797 obstructive sleep apnea Diseases 0.000 claims 1
- ISWRGOKTTBVCFA-UHFFFAOYSA-N pirfenidone Chemical compound C1=C(C)C=CC(=O)N1C1=CC=CC=C1 ISWRGOKTTBVCFA-UHFFFAOYSA-N 0.000 claims 1
- 229960003073 pirfenidone Drugs 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 229960003254 reslizumab Drugs 0.000 claims 1
- 229960004017 salmeterol Drugs 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 229950000835 tralokinumab Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20382764.7A EP3957308A1 (en) | 2020-08-21 | 2020-08-21 | (1r,3s)-3-((5-cyano-4-phenylthiazol-2-yl)carbamoyl)cyclopentane-1-carboxylic acid and derivatives thereof for use in the treatment of airway diseases |
| PCT/EP2021/073133 WO2022038261A1 (en) | 2020-08-21 | 2021-08-20 | (1r,3s)-3-((5-cyano-4-phenylthiazol-2-yl)carbamoyl)cyclopentane-1-carboxylic acid and derivatives thereof for use in the treatment of airway diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI4199922T3 true FI4199922T3 (fi) | 2024-12-05 |
Family
ID=72234795
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP21765908.5T FI4199922T3 (fi) | 2020-08-21 | 2021-08-20 | (1r,3s)-3-((5-syano-4-fenyylitiatsol-2-yyli)karbamoyyli)syklopentaani-1-karboksyylihappo käytettäväksi hengitystietautien hoidossa |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20230321053A1 (https=) |
| EP (2) | EP3957308A1 (https=) |
| JP (1) | JP7794807B2 (https=) |
| KR (1) | KR20230054444A (https=) |
| CN (1) | CN115942933A (https=) |
| AU (1) | AU2021327728A1 (https=) |
| BR (1) | BR112023002778A2 (https=) |
| CA (1) | CA3190081A1 (https=) |
| DK (1) | DK4199922T3 (https=) |
| ES (1) | ES3001104T3 (https=) |
| FI (1) | FI4199922T3 (https=) |
| HR (1) | HRP20241621T1 (https=) |
| HU (1) | HUE069338T2 (https=) |
| LT (1) | LT4199922T (https=) |
| MX (1) | MX2023002156A (https=) |
| PL (1) | PL4199922T3 (https=) |
| PT (1) | PT4199922T (https=) |
| RS (1) | RS66263B1 (https=) |
| SI (1) | SI4199922T1 (https=) |
| WO (1) | WO2022038261A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102460040B1 (ko) | 2016-04-27 | 2022-11-01 | 애브비 인코포레이티드 | 항-il-13 항체를 이용한 il-13 활성이 유해한 질환의 치료 방법 |
| US12162940B2 (en) | 2021-05-05 | 2024-12-10 | Immatics Biotechnologies Gmbh | BMA031 antigen binding polypeptides |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070219223A1 (en) | 2006-03-07 | 2007-09-20 | Endacea, Inc. | Compositions and methods for treating respiratory disorders |
| ES2331220B1 (es) | 2007-10-02 | 2010-09-23 | Palobiofarma, S.L. | Nuevos compuestos como antagonistas de los receptores a1 de adenosina. |
| KR20160061352A (ko) | 2013-10-15 | 2016-05-31 | 메디뮨 엘엘씨 | 벤랄리주맙을 사용하여 만성 폐쇄성 폐 질환을 치료하는 방법 |
| UA122670C2 (uk) * | 2014-09-08 | 2020-12-28 | Сефалон, Інк. | Спосіб лікування еозинофільної астми у пацієнта |
| ES2676535B1 (es) * | 2017-01-20 | 2019-04-29 | Palobiofarma Sl | Moduladores de los receptores a3 de adenosina |
| LT3592734T (lt) | 2017-03-06 | 2021-07-26 | Palobiofarma, S.L. | (1r,3s)-3-(5-ciano-4-fenil-1,3-tiazol-2-ilkarbamoil)ciklopentankarboksirūgšties amino druska |
-
2020
- 2020-08-21 EP EP20382764.7A patent/EP3957308A1/en not_active Withdrawn
-
2021
- 2021-08-20 RS RS20241285A patent/RS66263B1/sr unknown
- 2021-08-20 CA CA3190081A patent/CA3190081A1/en active Pending
- 2021-08-20 MX MX2023002156A patent/MX2023002156A/es unknown
- 2021-08-20 PL PL21765908.5T patent/PL4199922T3/pl unknown
- 2021-08-20 HU HUE21765908A patent/HUE069338T2/hu unknown
- 2021-08-20 FI FIEP21765908.5T patent/FI4199922T3/fi active
- 2021-08-20 DK DK21765908.5T patent/DK4199922T3/da active
- 2021-08-20 AU AU2021327728A patent/AU2021327728A1/en active Pending
- 2021-08-20 KR KR1020237009717A patent/KR20230054444A/ko active Pending
- 2021-08-20 CN CN202180051106.2A patent/CN115942933A/zh active Pending
- 2021-08-20 HR HRP20241621TT patent/HRP20241621T1/hr unknown
- 2021-08-20 LT LTEPPCT/EP2021/073133T patent/LT4199922T/lt unknown
- 2021-08-20 US US18/040,508 patent/US20230321053A1/en active Pending
- 2021-08-20 WO PCT/EP2021/073133 patent/WO2022038261A1/en not_active Ceased
- 2021-08-20 BR BR112023002778A patent/BR112023002778A2/pt unknown
- 2021-08-20 PT PT217659085T patent/PT4199922T/pt unknown
- 2021-08-20 EP EP21765908.5A patent/EP4199922B1/en active Active
- 2021-08-20 ES ES21765908T patent/ES3001104T3/es active Active
- 2021-08-20 JP JP2023512647A patent/JP7794807B2/ja active Active
- 2021-08-20 SI SI202130242T patent/SI4199922T1/sl unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20230321053A1 (en) | 2023-10-12 |
| EP3957308A1 (en) | 2022-02-23 |
| RS66263B1 (sr) | 2024-12-31 |
| JP2023538419A (ja) | 2023-09-07 |
| EP4199922B1 (en) | 2024-09-25 |
| DK4199922T3 (da) | 2024-11-25 |
| SI4199922T1 (sl) | 2025-03-31 |
| HRP20241621T1 (hr) | 2025-01-31 |
| KR20230054444A (ko) | 2023-04-24 |
| PT4199922T (pt) | 2024-12-18 |
| BR112023002778A2 (pt) | 2023-03-14 |
| LT4199922T (lt) | 2025-01-10 |
| AU2021327728A1 (en) | 2023-03-09 |
| JP7794807B2 (ja) | 2026-01-06 |
| CA3190081A1 (en) | 2022-02-24 |
| HUE069338T2 (hu) | 2025-02-28 |
| WO2022038261A1 (en) | 2022-02-24 |
| EP4199922A1 (en) | 2023-06-28 |
| MX2023002156A (es) | 2023-03-01 |
| ES3001104T3 (es) | 2025-03-04 |
| CN115942933A (zh) | 2023-04-07 |
| PL4199922T3 (pl) | 2025-02-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2156840B1 (en) | Use of mometasone furoate for treating airway passage and lung diseases | |
| AU2020226339B2 (en) | Methods of treatment of respiratory disorders | |
| JP5492072B2 (ja) | 喘息の増悪の予防および／または治療のためのフォルモテロールおよびジプロピオン酸ベクロメタゾンを含む組成物の使用 | |
| FI4199922T3 (fi) | (1r,3s)-3-((5-syano-4-fenyylitiatsol-2-yyli)karbamoyyli)syklopentaani-1-karboksyylihappo käytettäväksi hengitystietautien hoidossa | |
| JP2004507494A (ja) | サルメテロールとプロピオン酸フルチカゾンとの合剤の使用 | |
| AU2003292120A1 (en) | New synergistic combination comprising roflumilast and formoterol | |
| WO2018006001A1 (en) | Compositions and methods for treatment of copd | |
| US20020198228A1 (en) | Composition and method for the treatment of respiratory desease | |
| JPWO2022038261A5 (https=) | ||
| JP6188784B2 (ja) | 炎症性および免疫性疾患の治療のための組成物 | |
| US20250249007A1 (en) | Pharmaceutical compositions of ensifentrine for chronic obstructive pulmonary disease | |
| JP6021952B2 (ja) | 慢性閉塞性肺疾患の治療法 | |
| AU2010322066A1 (en) | Treatment of acute exacerbation of asthma and reduction of likelihood of hospitalization of patients suffering therefrom | |
| WO2026052051A1 (zh) | 杂环化合物在治疗肺疾病中的应用 | |
| HK1166934A (en) | Treatment of acute exacerbation of asthma and reduction of likelihood of hospitalization of patients suffering therefrom | |
| JP2013056925A (ja) | アンドラスト／グルココルチコイドの併用 | |
| HK1081861B (en) | New synergistic combination comprising roflumilast and formoterol |